Merck Reported Positive Tulisokibart Trial Results
A mid-stage study showed the drug reduced inflammatory skin lesions in patients with hidradenitis suppurativa.
Updated on Sept. 30, 2026 in Diseases — General
Live Poll
Do you trust that new prescription drugs are adequately tested before they reach the market?
Merck has reported positive results from a mid-stage clinical trial for its drug tulisokibart. The study focused on patients suffering from moderate-to-severe hidradenitis suppurativa.
Why it matters
These results offer potential new treatment pathways for patients dealing with hidradenitis suppurativa, a chronic skin condition that is often difficult to manage. The data provides early evidence of the drug's efficacy in significantly reducing inflammatory lesions.
In the trial, 41% of patients treated with the drug achieved a 75% reduction in skin lesions, compared to 15% in the placebo group. The safety profiles for those receiving the treatment were found to be comparable to those who received a placebo.
The players
Merck
Merck is a global pharmaceutical company that researches and develops a wide array of medications and vaccines.
The details
The study tracked the reduction of inflammatory skin lesions over a 16-week treatment period. Researchers compared the clinical outcomes of patients receiving the highest dose of tulisokibart against a control group that was administered a placebo.
Timeline
The clinical study observation period lasted 16 weeks.
Merck reported the mid-stage study results on September 30, 2026.
Health Landscape
This development contributes to the clinical development pipeline for hidradenitis suppurativa therapies, which has historically lacked diverse treatment options. The results signal a potential shift in how chronic, inflammatory skin conditions are addressed through targeted drug intervention.
The results provide hope for patients who have struggled to find effective management strategies for moderate-to-severe hidradenitis suppurativa. Patients should consult their healthcare providers as research continues to determine the future availability and safety profile of this potential treatment.
The takeaway
This study indicates that targeted drug therapy can produce a statistically significant reduction in inflammatory lesions for patients with chronic skin conditions. The comparable safety profiles suggest that this treatment could eventually serve as a viable alternative for patients needing symptom relief.
Further reading
For more information on ongoing pharmaceutical developments, visit the Diseases — General section.
Live Poll
Do you trust that new prescription drugs are adequately tested before they reach the market?
